Print PagePrint Page
E-mail PageE-mail Page
RSS FeedsRSS Feeds
X
Share Page
E-mail AlertsE-mail Alerts
IR ContactsIR Contacts

2016 Press Releases

Webcast ImageWebcast
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference (Live)
04/04/17 at 4:20 p.m. ET
vTv Therapeutics Inc. at Needham & Co. 16th Annual Healthcare Conference
Tuesday, April 4, 2017 4:20 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle 
12/14/16vTv Therapeutics Announces Positive Topline Results from Phase 2 Study of TTP273 in Type 2 Diabetes
Oral small molecule GLP-1 receptor agonist met primary endpoint Company’s second successful Phase 2 diabetes trial in 2016 HIGH POINT, N.C.--(BUSINESS WIRE)--Dec. 14, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT) today announced positive data from its Phase 2 study evaluating TTP273, an oral small molecule GLP-1 receptor (GLP-1R) agonist, for the treatment of Type 2 diabetes. TTP273 demonstrated a statistically significant reduction in Hb... 
Printer Friendly Version
11/16/16New Pre-Clinical Data on a vTv Therapeutics Small Molecule Drug Candidate Against Parkinson’s Disease to be Presented at the Society for Neuroscience 2016 Meeting in San Diego
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 16, 2016-- vTv Therapeutics Inc. (vTv, Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered small molecule drug candidates to fill significant unmet medical needs, today announced that Dr. Bobby Thomas, Associate Professor at Medical College of Georgia, Georgia Regents University at Augusta, will present a poster at the Society for Neuro... 
Printer Friendly Version
11/10/16vTv Therapeutics to Participate in Upcoming Mizuho, Stifel and Piper Jaffray Conferences
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 10, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that it will be participating in the following conferences: Global Mizuho Investor Conference (MIC) NY on Monday, November 14 in New York. Stifel 201... 
Printer Friendly Version
11/02/16vTv Therapeutics Reports Third Quarter Financial and Operational Results and Recent Highlights
HIGH POINT, N.C.--(BUSINESS WIRE)--Nov. 2, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and reported financial and operational results for the third quarter ended September 30, 2016. “This was a very productive quarter as we continued the advancement... 
Printer Friendly Version
10/24/16vTv Therapeutics to Present at Peptide Therapeutics Symposium
HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 24, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the company’s Chief Scientific Officer Carmen Valcarce, Ph.D., will speak at the 11th Annual Peptide Therapeutics Symposium at the Salk Institute for Biological Studies in La Jolla, Califor... 
Printer Friendly Version
10/03/16vTv Therapeutics to Present at Neuro Advance Boston
HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 3, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company committed to the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, announced today that company Chief Medical Officer, Dr. Larry Altstiel, MD, PhD, will speak on a panel at Neuro Advance Boston hosted by Harvard Medical School. Dr. Altstiel will participate on the panel “Nove... 
Printer Friendly Version
09/08/16vTv Therapeutics to Present at the Rodman & Renshaw Global Investment Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 8, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will present a corporate overview at the Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The company’s management will be p... 
Printer Friendly Version
09/07/16vTv Therapeutics Completes Enrollment of Part A of Pivotal Phase 3 Trial Evaluating Azeliragon for the Treatment of Patients with Mild Alzheimer’s Disease
Phase 2b Trial Showed Positive Results In Slowing Cognitive Decline HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 7, 2016-- vTv Therapeutics Inc. (NASDAQ:VTVT) today announced the completion of enrollment for Part A of STEADFAST (Single Trial Evaluating Alzheimer’s Disease Following Addition to Symptomatic Therapy), vTv’s Phase 3 placebo-controlled trial of azeliragon, an oral antagonist of the Receptor for Advanced Glycation Endproducts (RAGE), fo... 
Printer Friendly Version
09/02/16vTv Therapeutics to Present at the International Psychogeriatric Association International Congress
HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 2, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that company Chief Medical Officer Dr. Larry Altstiel, MD, PhD will be giving a platform presentation titled “Clinical Support for Advancement of the RAGE Antagonist Azeliragon into Phase 3 Clini... 
Printer Friendly Version
08/16/16vTv Therapeutics Completes Enrollment of Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Company Releases Q2 Earnings Results and Details Upcoming Program Milestones HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 16, 2016-- vTv Therapeutics Inc. (vTv) (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the com... 
Printer Friendly Version
08/10/16CORRECTING and REPLACING vTv Therapeutics Announces Positive Topline Results from Phase 2b Study of Glucokinase Activator TTP399 in Type 2 Diabetes
Novel glucokinase activator shows sustained meaningful reduction in HbA1c with well-tolerated treatment regimen HIGH POINT, N.C.--(BUSINESS WIRE)--Aug. 10, 2016-- Please replace the release with the following corrected version due to multiple revisions. The corrected release reads: VTV THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF GLUCOKINASE ACTIVATOR TTP399 IN TYPE 2 DIABETES Novel gluc... 
Printer Friendly Version
07/27/16vTv Therapeutics Announces Presentation of Phase 2b Azeliragon Results at the 2016 Alzheimer’s Association International Conference (AAIC)
Analysis shows azeliragon 5mg/day resulted in steadily increasing delay in time to cognitive deterioration in mild Alzheimer’s disease patients Azeliragon designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation TORONTO--(BUSINESS WIRE)--Jul. 27, 2016-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally... 
Printer Friendly Version
07/14/16vTv Therapeutics Announces Phase 2b Azeliragon Data Selected for Oral Presentation at the 2016 Alzheimer’s Association International Conference
Azeliragon MOA designed to inhibit RAGE, which affects Aβ accumulation, tau hyperphosphorylation and chronic inflammation – three of the principal causes of neuronal damage in AD HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that... 
Printer Friendly Version
07/06/16vTv Therapeutics to Present at Cantor Fitzgerald's 2nd Annual Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Jul. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Company management will present a corporate overview at Cantor Fitzgerald’s 2nd Annual Healthcare Conference on Wednesday, July 13, 2016 at 8:00 a.m. ET in New York City. A li... 
Printer Friendly Version
06/14/16vTv Therapeutics Presents Positive Results from a Pilot Study of its Glucokinase Activator at American Diabetes Association 76th Scientific Sessions
Data show TTP399 improves glycemic control and insulin resistance without hypoglycemia NEW ORLEANS--(BUSINESS WIRE)--Jun. 14, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that results from an earlier pilot clinical study of TTP399, its liver-selective glucokinase activato... 
Printer Friendly Version
05/12/16vTv Therapeutics Reports First Quarter Financial and Operational Results
HIGH POINT, N.C.--(BUSINESS WIRE)--May 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today provided a corporate update and reported financial and operational results for the first quarter ended March 31, 2016. “We are pleased to report a highly productive first quarter, as we cont... 
Printer Friendly Version
04/20/16vTv Therapeutics Presents Data on Two Diabetes Candidates at Keystone Symposia on New Therapeutics for Diabetes and Obesity
Data featured in an oral presentation show TTP273 is the first GLP-1R agonist without significant gastrointestinal side effects HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 20, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that data from studies of its orally available, small molecule... 
Printer Friendly Version
04/12/16vTv Therapeutics Announces Presentations on its Diabetes Product Candidates TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity
HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 12, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that the Company has been selected for oral and poster presentations on its diabetes product candidates, TTP273 and TTP399 at the Keystone Symposia on New Therapeutics for Diabetes and Obesity. ... 
Printer Friendly Version
04/06/16vTv Therapeutics to Present at the 15th Annual Needham Healthcare Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Apr. 6, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at the 15th Annual Needham Healthcare Conference on Tuesday, April 1... 
Printer Friendly Version
03/04/16vTv Therapeutics to Present at Two Investor Conferences in March
HIGH POINT, N.C.--(BUSINESS WIRE)--Mar. 4, 2016-- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at two investor conferences in March. Presentation D... 
Printer Friendly Version
03/01/16vTv Therapeutics Reports Fourth Quarter and Full Year 2015 Financial and Operational Results and Recent Highlights
- Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer’s disease - Completed enrollment of AGATA Phase 2b study with liver-selective Glucokinase Activator in Type 2 diabetes, with expected data readout in mid-2016 - Initiated LOGRA Phase 2b study with oral GLP-1R agonist in Type 2 diabetes, with expected data readout by year-end 2016 - Raised $104 million in net proceeds from IPO HIGH POINT, N.C.... 
Printer Friendly Version
02/22/16vTv Therapeutics Reports Preclinical and Clinical Results on its Diabetes Candidate TTP273
Data presented at Keystone Symposia on Molecular and Cellular Biology KEYSTONE, Colo.--(BUSINESS WIRE)--Feb. 22, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that data from studies of its oral, small molecule GLP-1R agonist were reported at the Keystone Symposia on G-Protein Cou... 
Printer Friendly Version
02/09/16vTv Therapeutics Completes Enrollment of Phase 2b Trial Evaluating TTP399 for the Treatment of Type 2 Diabetes
Oral Glucokinase Activator has potential to address an underlying cause of Type 2 diabetes Company expects to report topline results in mid-2016 HIGH POINT, N.C.--(BUSINESS WIRE)--Feb. 9, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the completion of patient enrol... 
Printer Friendly Version
01/28/16vTv Therapeutics to Present at the 18th Annual BIO CEO & Investor Conference
HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 28, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe, President and CEO and Dr. Larry Altstiel, EVP, Chief Medical Officer, will present a corporate overview at the 18th Annual BIO CEO & Investor Conference on Tuesday, ... 
Printer Friendly Version
01/21/16vTv Therapeutics Initiates Phase 2 Trial Evaluating TTP273 for the Treatment of Type 2 Diabetes
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Topline results are expected at the end of 2016 HIGH POINT, N.C.--(BUSINESS WIRE)--Jan. 21, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced the enrollment of the first patients in the Compa... 
Printer Friendly Version